Phaseline

Companies › Cynata Therapeutics

Cynata Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Immunology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CYP-001
Cymerus induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs)
–Phase 2Graft Versus Host Disease, Acute–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05643638CYP-001Phase 2Graft Versus Host Disease, AcuteImmunologyMar 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Jiangsu Renocell Biotech Company Wuxi Cellular Biopharmaceutical Group Artiva Biotherapeutics Kyverna Therapeutics Apogee Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.